Simtra BioPharma Solutions’ Post

Today marks the first day of trading in Trill Impact’s portfolio company Cinclus Pharma on Nasdaq Stockholm. The listing is an important milestone that enables continued development of the company’s drug candidate linaprazan glurate, which aims to improve the medical outcomes for patients suffering from severe stomach acid-related disorders worldwide.   Nina Rawal, Partner at Trill Impact Advisory and Co-head of Trill Impact Ventures was present when the opening bell rang this morning.   “It is of course very exciting to see Cinclus Pharma being listed on Nasdaq Stockholm today. To us, the fact that Cinclus Pharma has attracted investor interest in the current financial climate, is a great testament to the quality of the asset and the strong management team. When Trill Impact invested in Cinclus Pharma a couple of years back, we were confident that the company had the potential to become a global leader in the treatment of severe gastric acid-related disease. Since then, the company has reported strong Phase II data and is now ready to move into the final stage of clinical development". Read more about the #IPO here: https://lnkd.in/d7tvcBPC #impactinvesting #biotech #healthcare #lifescience #SDG3

MST Financial is proud to have supported Opthea Ltd (OPT.ASX) acting as Sole Lead Manager to the company’s A$227 million capital raising – the largest pre-Phase 3 readout biotech raise ever in Australia (ex CSL). The capital raising comprised of a A$10.0 million Institutional Placement and a $217.3 million accelerated non renounceable entitlement offer (ANREO). Proceeds of the offer will be used to continue advancing clinical development of OPT-302 for the treatment of wet AMD, including progressing the Phase 3 clinical program, CMC (chemistry, manufacturing, and controls) activities and Biologics License application (BLA) preparations. OPT-302 treats wet AMD, the leading cause of irreversible blindness, by improving vision in patients. #MSTFinancial #OptheaLtd #OPT #growthcapital #australianequities #ASX #finance #retinalspecialists #wetAMD #ophthalmology #macular #degeneration

Exciting news! Scinai Immunotherapeutics Ltd. 𝐫𝐞𝐜𝐞𝐢𝐯𝐞𝐬 𝐚𝐧 𝐮𝐩𝐝𝐚𝐭𝐞𝐝 𝐋𝐞𝐭𝐭𝐞𝐫 𝐨𝐟 𝐈𝐧𝐭𝐞𝐧𝐭 (𝐋𝐨𝐈) 𝐟𝐫𝐨𝐦 𝐭𝐡𝐞 European Investment Bank (EIB) 𝐨𝐮𝐭𝐥𝐢𝐧𝐢𝐧𝐠 𝐬𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐭𝐞𝐫𝐦𝐬 𝐟𝐨𝐫 𝐜𝐨𝐧𝐯𝐞𝐫𝐭𝐢𝐧𝐠 𝐭𝐡𝐞 𝐦𝐚𝐣𝐨𝐫𝐢𝐭𝐲 𝐨𝐟 𝐭𝐡𝐞 𝐄𝐈𝐁’𝐬 𝐥𝐨𝐚𝐧 𝐢𝐧𝐭𝐨 𝐞𝐪𝐮𝐢𝐭𝐲 𝐭𝐡𝐫𝐨𝐮𝐠𝐡 𝐩𝐫𝐞𝐟𝐞𝐫𝐫𝐞𝐝 𝐬𝐡𝐚𝐫𝐞𝐬.  - The shares are convertible into American Depositary Shares (ADSs), representing 19.5% of the fully diluted capital of the company at the time of closing. Notably, there are no anti-dilution rights.  - The updated LoI does not require a variable remuneration, which in the previous LOI included a 3% royalty on the Company's revenues and 5% of any equity raise up to a limit of EUR 70 million, nor does it provide for mandatory dividends or mandatory redemption.  - The loan amount that would be converted is approximately $28 million, while approximately $270,000 will stay as a loan payable on Dec 31st, 2031.  𝐓𝐡𝐢𝐬 𝐬𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐜 𝐦𝐨𝐯𝐞 𝐜𝐨𝐮𝐥𝐝 𝐢𝐦𝐦𝐞𝐝𝐢𝐚𝐭𝐞𝐥𝐲 𝐞𝐥𝐢𝐦𝐢𝐧𝐚𝐭𝐞 𝐭𝐡𝐞 𝐬𝐡𝐚𝐫𝐞𝐡𝐨𝐥𝐝𝐞𝐫𝐬’ 𝐝𝐞𝐟𝐢𝐜𝐢𝐭 𝐨𝐟 $𝟓.𝟏 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 (𝐚𝐬 𝐨𝐟 𝐌𝐚𝐫𝐜𝐡 𝟑𝟏𝐬𝐭, 𝟐𝟎𝟐𝟒) 𝐚𝐧𝐝 𝐜𝐫𝐞𝐚𝐭𝐞 𝐚 𝐬𝐮𝐫𝐩𝐥𝐮𝐬 𝐢𝐧 𝐬𝐡𝐚𝐫𝐞𝐡𝐨𝐥𝐝𝐞𝐫𝐬’ 𝐞𝐪𝐮𝐢𝐭𝐲. 𝑻𝒉𝒂𝒏𝒌 𝒚𝒐𝒖, #𝑬𝑰𝑩 𝒇𝒐𝒓 𝒕𝒉𝒊𝒔 𝒗𝒐𝒕𝒆 𝒐𝒇 𝒄𝒐𝒏𝒇𝒊𝒅𝒆𝒏𝒄𝒆 𝒊𝒏 Scinai Immunotherapeutics Ltd. 𝒂𝒏𝒅 𝒐𝒖𝒓 𝒗𝒊𝒔𝒊𝒐𝒏. 𝑻𝒉𝒊𝒔 𝒊𝒔 𝒂 𝒎𝒂𝒔𝒔𝒊𝒗𝒆 𝒗𝒂𝒍𝒊𝒅𝒂𝒕𝒊𝒐𝒏 𝒐𝒇 𝒐𝒖𝒓 𝑹&𝑫 𝒂𝒏𝒅 𝑪𝑫𝑴𝑶 𝒔𝒕𝒓𝒂𝒕𝒆𝒈𝒚. Read the press release >>https://lnkd.in/dqYXgxzT #NASDAQ #EIB #growth #biotech #partnership #companynews #pressrelease

When choosing a CDMO, the stakes could not be higher. It's important to consider not only the capabilities and technical expertise that align with your project, there must be aligned values, and a shared commitment to open communication and partnership. Right from the start, Serán BioScience's teams are carefully considering your molecule profile, target patient profile and business goals when developing a project plan. Whether you're dealing with solubility or permeability concerns or you have limited material available, our teams will leverage their experience and expertise to develop an appropriate formulation strategy to meet your program's unique needs. Find out how Serán BioScience can support your program, right from the start! https://hubs.li/Q02z8n_r0 #CDMO #Partnership #drugformulation

Check out this webinar with Chris Dokomajilar on January 16th to see what the year may look like for biopharma dealmaking in 2024! #venturecapital #biotech #biopharma #pharma #dealmaking #2024predictions

A look at biopharma’s most highly valued yet unpartnered assets features Karuna, Ventyx and regular bridesmaid Ascendis. Unpartnered assets - should more prominent players swoop in or swerve them entirely? The Evaluate Vantage team has run a new analysis on some of the most significant unpartnered assets in the pipeline to look at which might be destined for a deal and which are headed for a solo journey. This is an emerging area of interest from private investors and mid-size Pharma. There might be more activity coming up later this year. https://lnkd.in/d-s5C8Ww

Nonceba Sibanda, GMP Scientist USP at Rentschler Biopharma, said it best, "You're helping people who help people. We make a brilliant team". And we cannot agree more! See how a collaboration with Cytiva is bringing Rentschler Biopharma both efficiency and flexibility to their operations. The ultimate goal? Improving more patients’ lives. Watch the full story here: https://lnkd.in/eg7_Zqtk #CDMO #viralvectors #genomicmedicine #genetherapy

Nonceba Bokuvha Sibanda, GMP Scientist USP at Rentschler Biopharma SE , said it best, "You're helping people who help people. We make a brilliant team". And we cannot agree more! See how a collaboration with Cytiva is bringing Rentschler Biopharma both efficiency and flexibility to their operations. The ultimate goal? Improving more patients’ lives. Watch the full story here: https://lnkd.in/dxTmVi9k #CDMO #viralvectors #genomicmedicine #genetherapy

Nonceba Sibanda, GMP Scientist USP at Rentschler Biopharma, said it best, "You're helping people who help people. We make a brilliant team". And we cannot agree more! See how a collaboration with Cytiva is bringing Rentschler Biopharma both efficiency and flexibility to their operations. The ultimate goal? Improving more patients’ lives. Watch the full story here: https://lnkd.in/ePYbrKDf #CDMO #viralvectors #genomicmedicine #genetherapy

Nonceba Sibanda, GMP Scientist USP at Rentschler Biopharma, said it best, "You're helping people who help people. We make a brilliant team". And we cannot agree more! See how a collaboration with Cytiva is bringing Rentschler Biopharma both efficiency and flexibility to their operations. The ultimate goal? Improving more patients’ lives. Watch the full story here: https://lnkd.in/evgyJdbm #CDMO #viralvectors #genomicmedicine #genetherapy